<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Role of surgery in patients with metastatic renal cell carcinoma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Role of surgery in patients with metastatic renal cell carcinoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Role of surgery in patients with metastatic renal cell carcinoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jerome P Richie, MD, FACS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Toni K Choueiri, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael B Atkins, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Wenliang Chen, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 06, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Patients who present with metastatic renal cell carcinoma (RCC) or who develop metastases or recurrent disease following prior treatment are generally managed with systemic therapy, primarily using immunotherapy or agents targeting the vascular endothelial growth factor (VEGF) pathways. (See  <a class="medical medical_review" href="/d/html/2984.html" rel="external">"Systemic therapy of advanced clear cell renal carcinoma"</a>.)</p><p>However, not all patients with metastatic RCC behave similarly; some data suggest that there may be a subgroup whose tumors will display an indolent growth pattern that may warrant careful surveillance rather than active surgical or medical therapy [<a href="#rid1">1</a>]. Regardless, most patients with metastatic RCC will require treatment, and surgery is sometimes part of the therapeutic plan.</p><p>This topic will discuss the role of surgery in patients with metastatic RCC. Other topics relevant to this population are discussed separately. (See  <a class="medical medical_review" href="/d/html/15719.html" rel="external">"Overview of the treatment of renal cell carcinoma", section on 'Advanced renal cell carcinoma'</a>.)</p><p>The role of surgery in the initial management of patients with localized RCC is discussed separately. (See  <a class="medical medical_review" href="/d/html/2985.html" rel="external">"Definitive surgical management of renal cell carcinoma"</a>.)</p><p class="headingAnchor" id="H270848330"><span class="h1">OVERVIEW OF SURGICAL TREATMENT FOR METASTATIC RENAL CELL CARCINOMA</span><span class="headingEndMark"> — </span>Surgery continues to play an important role in the management of patients with metastatic renal cell carcinoma (RCC) in one of several ways  (<a class="graphic graphic_algorithm graphicRef109427" href="/d/graphic/109427.html" rel="external">algorithm 1</a>): </p><p class="bulletIndent1"><span class="glyph">●</span>Nephrectomy may be performed as part of a combined modality approach either to decrease tumor burden prior to systemic therapy or to resect residual abnormalities in patients exhibiting major responses to systemic therapy. (See <a class="local">'Cytoreductive nephrectomy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Metastasectomy may be performed in patients with one or a very limited number of metastases. (See <a class="local">'Metastasectomy'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Palliative nephrectomy may be performed to control severe local and systemic symptoms from the primary tumor. (See <a class="local">'Palliative nephrectomy'</a> below.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">CYTOREDUCTIVE NEPHRECTOMY</span><span class="headingEndMark"> — </span>Cytoreductive nephrectomy (sometimes referred to as debulking nephrectomy) is a reasonable treatment option for carefully selected patients with metastatic renal cell carcinoma (RCC). </p><p>In general, we offer cytoreductive nephrectomy before systemic therapy to patients with no or one risk factor and good performance status (see <a class="local">'Patient selection for cytoreductive nephrectomy'</a> below). Patients with more advanced disease (≥2 risk factors) should receive systemic therapy first but may benefit from nephrectomy subsequently if they demonstrate good response to systemic therapy. </p><p>The majority of patients will undergo systemic therapy after cytoreductive nephrectomy; only a small group of patients who have indolent disease or no evidence of disease (M1NED) can be observed. If systemic therapy is given first, patients should generally be restaged in 8 to 12 weeks; those who have a major response may be considered for cytoreductive nephrectomy then. However, there is considerable variability in the timing of restaging and the eligibility criteria for cytoreductive nephrectomy after systemic therapy, depending upon both the systemic therapy used and clinician preference. </p><p>A multidisciplinary consultation that includes discussion of the patient's prognosis, the radiologic features of the primary and metastatic sites, the proposed systemic treatment options, and the potential need for establishing a histologic diagnosis prior to surgery is recommended to formulate an appropriate plan for each patient. </p><p>The possible benefit of retroperitoneal lymphadenectomy in the context of nephrectomy and systemic therapy for patients presenting with stage IV disease has not been well studied  (<a class="graphic graphic_table graphicRef110735" href="/d/graphic/110735.html" rel="external">table 1</a>) [<a href="#rid2">2-4</a>], but at least one report suggests that there is no advantage to this approach [<a href="#rid2">2</a>]. Other data suggest that the presence of retroperitoneal nodes is a strong predictor of systemic treatment failure.</p><p class="headingAnchor" id="H270848430"><span class="h2">Patient selection for cytoreductive nephrectomy</span><span class="headingEndMark"> — </span>There is no universal approach to selection of the appropriate patient with metastatic RCC who should be offered cytoreductive nephrectomy. For patients who are deemed to be candidates for cytoreductive nephrectomy, clinical trial participation should be encouraged. </p><p>In general, the selection of patients should be done with considerable care so that appropriate patients can proceed with systemic therapy. This is best ensured by taking into consideration both the patient's performance status (usually assessed by the Karnofsky performance status [KPS]) and their prognosis. Two very similar models are widely used to predict the patient's prognosis, containing five and six variables, respectively. Each of these variables is called a risk factor, and the total number of risk factors is an important determinant of a patient's eligibility for upfront cytoreductive nephrectomy. (See <a class="local">'Cytoreductive nephrectomy'</a> above.)</p><p>The Memorial Sloan Kettering Cancer Center (MSKCC) model includes five variables [<a href="#rid5">5</a>]. Patients with none, one to two, and three to five of these factors are considered good, intermediate, and poor risk, respectively. </p><p class="bulletIndent1"><span class="glyph">●</span>&lt;1 year from diagnosis to treatment</p><p class="bulletIndent1"><span class="glyph">●</span>KPS &lt;80 </p><p class="bulletIndent1"><span class="glyph">●</span>Serum lactate dehydrogenase (LDH) &gt;1.5 times the upper limit of normal</p><p class="bulletIndent1"><span class="glyph">●</span>Corrected serum calcium &gt; upper limit of normal</p><p class="bulletIndent1"><span class="glyph">●</span>Serum hemoglobin &lt; lower limit of normal</p><p></p><p>Another model from the International Metastatic Database Consortium (IMDC) includes six variables [<a href="#rid6">6</a>]. Patients with none, one to two, and three to six of these factors are considered good, intermediate, and poor risk, respectively.</p><p class="bulletIndent1"><span class="glyph">●</span>&lt;1 year from diagnosis to treatment</p><p class="bulletIndent1"><span class="glyph">●</span>KPS &lt;80 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Corrected serum calcium &gt; upper limit of normal</p><p class="bulletIndent1"><span class="glyph">●</span>Serum hemoglobin &lt; lower limit of normal</p><p class="bulletIndent1"><span class="glyph">●</span>Absolute neutrophil count &gt; upper limit of normal</p><p class="bulletIndent1"><span class="glyph">●</span>Platelet count &gt; upper limit of normal</p><p></p><p>Further discussion of prognostic factors for patients with metastatic RCC is covered separately. (See  <a class="medical medical_review" href="/d/html/2961.html" rel="external">"Prognostic factors in patients with renal cell carcinoma", section on 'Prognostic factors in stage IV disease'</a>.)</p><p class="headingAnchor" id="H796639986"><span class="h2">Evidence for cytoreductive nephrectomy</span><span class="headingEndMark"> — </span>The role for cytoreductive nephrectomy in metastatic RCC was established in the cytokine era but extrapolated to the current practice in which more effective therapies (eg, vascular endothelial growth factor [VEGF] tyrosine kinase inhibitors [TKIs] and immune checkpoint inhibitors [ICIs]) are favored. </p><p class="headingAnchor" id="H1599447588"><span class="h3">Cytokine therapy</span><span class="headingEndMark"> — </span>The primary support for cytoreductive nephrectomy comes from two trials conducted in the era of interferon immunotherapy, which is no longer used as a first-line therapy for RCC:</p><p class="bulletIndent1"><span class="glyph">●</span>The Southwest Oncology Group (SWOG) randomly assigned 246 patients presenting with metastatic RCC to treatment with nephrectomy followed by interferon alfa (IFNa) versus IFNa alone [<a href="#rid7">7</a>]. Compared with IFNa alone, nephrectomy before treatment resulted in a statistically significant improvement in overall survival (median 11 versus 8 months). Among those who underwent nephrectomy plus IFNa, patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 survived longer than those with a performance status of 1 (median 17 versus 7 months)  (<a class="graphic graphic_table graphicRef72901" href="/d/graphic/72901.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a second trial sponsored by the European Organization for Research and Treatment of Cancer (EORTC), 83 patients with metastatic RCC were randomly assigned to the same treatment arms as in the SWOG study above [<a href="#rid8">8</a>]. Both time to progression (median five versus three months) and overall survival duration (median 17 versus 7 months) significantly favored cytoreductive nephrectomy prior to IFNa therapy.</p><p></p><p class="headingAnchor" id="H4255752"><span class="h3">Antiangiogenic therapy and immune checkpoint inhibitors</span><span class="headingEndMark"> — </span>Whether to offer cytoreductive nephrectomy to patients undergoing modern (antiangiogenic or ICI) systemic therapy for metastatic RCC is less straightforward. </p><p>Nevertheless, rapid advances in immunotherapy with ICIs have led to this approach being the preferred treatment for metastatic RCC. (See  <a class="medical medical_review" href="/d/html/15719.html" rel="external">"Overview of the treatment of renal cell carcinoma", section on 'Checkpoint inhibitor immunotherapy'</a>.)</p><p>Although upfront cytoreductive nephrectomy was once considered to be an option in such patients with projected survival &gt;12 months and &lt;4 poor prognostic factors, it was not supported by available prospective data:</p><p class="bulletIndent1"><span class="glyph">●</span>In the CARMENA trial, 450 patients were randomly assigned to nephrectomy followed by <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a> or sunitinib alone [<a href="#rid9">9</a>]. All patients had intermediate- or poor-risk metastatic RCC. With a median follow-up of 51 months and 326 observed deaths, results with sunitinib alone met the predetermined criteria for noninferiority compared with those with nephrectomy followed by sunitinib (median overall survival 18.4 months with sunitinib versus 13.9 months with surgery followed by targeted therapy, hazard ratio for death 0.89, 95% CI 0.71-1.10). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A second trial, SURTIME, was terminated prematurely due to poor accrual after enrolling just 99 predominantly MSKCC intermediate-risk patients [<a href="#rid10">10</a>]. Compared with upfront nephrectomy, more patients who underwent deferred nephrectomy (after three cycles of <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a>) received sunitinib, and the overall survival was better after delayed nephrectomy than upfront nephrectomy (32 versus 15 months).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Largely based on the results of these two trials, the 2018 updated European Association of Urology guidelines recommended against cytoreductive nephrectomy for MSKCC poor-risk patients and against <strong>upfront</strong> cytoreductive nephrectomy for MSKCC intermediate-risk patients (with two risk factors) requiring systemic therapy with antiangiogenic agents [<a href="#rid11">11</a>]. MSKCC intermediate-risk patients who derive long-term sustained benefit and/or have minimal residual metastatic burden after vascular endothelial growth factor receptor (VEGFR-TKI) therapy may be considered for delayed nephrectomy. </p><p></p><p>The results of the CARMENA trial are in contrast to retrospective data. Notably, however, retrospective data are limited by the inherent selection bias of which patients were referred for surgery. </p><p class="bulletIndent1"><span class="glyph">●</span>A follow-up analysis of the CARMENA trial showed that cytoreductive nephrectomy might be beneficial for patients with only one IMDC risk factor [<a href="#rid12">12</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One study included almost 1700 patients from the IMDC, all of whom were treated with antiangiogenic agents [<a href="#rid13">13</a>]. Compared with patients who did not undergo cytoreductive nephrectomy, those who underwent surgery had significantly longer overall survival (median 20.6 versus 9.6 months, respectively). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One study from the National Cancer Database identified patients with metastatic RCC treated with antiangiogenic agents between 2006 and 2013 [<a href="#rid14">14</a>]. Of the 15,390 patients treated, 5374 (35 percent) underwent cytoreductive nephrectomy. Overall survival was significantly longer in patients managed with cytoreductive nephrectomy compared with those without cytoreductive nephrectomy (median 17.1 versus 7.7 months). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective study from IMDC presented in abstract form at the 2020 American Society of Clinical Oncology (ASCO) GU meeting included 4639 patients with metastatic RCC from 40 centers. Cytoreductive nephrectomy was more likely in patients with the following characteristics: &lt;65 years old, no adverse metastases, IMDC risk score of 0 or 1, and no adverse histology (non-clear-cell or sarcomatoid features). By univariate, multivariate, and propensity-score matched analyses, cytoreductive nephrectomy was associated with improved overall survival compared with no cytoreductive nephrectomy. The benefit of cytoreductive nephrectomy did not differ between patients treated with first-line antiangiogenic versus ICI therapy [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective study from Memorial Sloan Kettering Cancer Center of 245 patients with metastatic RCC found the total IMDC risk factors changed in more than half of the patients at six weeks and six months after cytoreductive nephrectomy; an increase in the number of IMDC risk factors is a negative prognostic factor [<a href="#rid16">16</a>]. Thus, the systemic benefit of cytoreductive nephrectomy, through significant lowering of the disease burden, may manifest in modifying patients' IMDC scores.</p><p></p><p>The preponderance of data from prospective and retrospective studies suggest that patients with low disease burden and good performance status may still benefit from cytoreductive nephrectomy, regardless of the choice of systemic therapy [<a href="#rid17">17</a>]. Thus, we can offer nephrectomy in patients with one risk factor and good performance status but reserve nephrectomy for others with two or more risk factors and/or poor performance status until after they have demonstrated good response to systemic therapy. </p><p>Although there are no prospective data on the role of cytoreductive nephrectomy in the setting of ICI, we suggest following the same guidelines with regard to cytoreductive nephrectomy as with antiangiogenic therapy before initiating systemic therapy. </p><p>Three clinical trials, NORDIC-SUN (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03977571&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPPTZr1ltbU1Gp2uy1ffeIMdGnde9wpoj7YkiJYN0FyzEg%3D%3D&amp;TOPIC_ID=2963" target="_blank">NCT03977571</a>), CYTOSHRINK (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.urotoday.com%2Fclinical-trials%2Fkidney-renal-cancer%2F119350-cytoreductive-stereotactic-hypofractionated-radiotherapy-with-combination-ipilimumab-nivolumab-for-metastatic-kidney-cancer.html&amp;token=HYaDXd9ibZatoTQEXFXeSrW2HOGYmkhQihYTeppa8Nz1JHaEkjNfWOdoqsnG%2B8laU6DWCl8yz160BW6KvNJY9m0oLXwfohglBigpWoseRlxeUvBK1pZzqSwmkZhvbF6SgTnjUJ5P%2F4eL3Pl9iaME0Bah%2FgpNstP%2FumcW8Xhwbqo6j%2Bf7Jl9E5%2BtQ1f8gQQrbrwC1JCwUsNIWoeWxLU0oqw%3D%3D&amp;TOPIC_ID=2963" target="_blank">NCT04090710</a>), and PROBE (SWOG, under development), that are underway should help answer the question of which patients in the ICI era will benefit from cytoreductive nephrectomy.</p><p class="headingAnchor" id="H3"><span class="h1">METASTASECTOMY</span><span class="headingEndMark"> — </span>In selected patients with metastatic renal cell carcinoma (RCC), surgical resection of metastatic foci, known as metastasectomy, is a treatment option that can yield long-term disease-free survival. </p><p>Resection of metastatic disease (metastasectomy) has been performed in several situations:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with stage IV disease at presentation, where metastasectomy is performed with nephrectomy</p><p class="bulletIndent1"><span class="glyph">●</span>Patients who develop metastatic disease following nephrectomy</p><p class="bulletIndent1"><span class="glyph">●</span>Patients who have persistent disease despite systemic therapy</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Patient selection for metastasectomy</span></p><p class="headingAnchor" id="H2131272260"><span class="h3">Metastasectomy before systemic therapy</span><span class="headingEndMark"> — </span>Patients eligible for metastasectomy prior to systemic therapy must have limited "oligometastatic" disease (ie, one to three metastases). Those who develop metastatic disease following nephrectomy should have a disease-free interval of &gt;1 year. Following complete metastasectomy, these patients are <strong>not</strong> placed on adjuvant therapy until recurrence outside of clinical trials. </p><p>The potential role of surgery is illustrated by the results from a classic series of 278 patients with recurrent RCC in which 51 percent underwent removal of all of their metastatic disease with curative intent, 25 percent underwent partial resection of their metastatic disease, and 24 percent were treated without surgery [<a href="#rid18">18</a>]. Metastases were most frequently resected from the lung, brain, bone, and soft tissue. </p><p>The following findings were noted on multivariate analysis:</p><p class="bulletIndent1"><span class="glyph">●</span>The five-year overall survival rate was highest in patients treated with curative-intent metastasectomy (44 versus 14 and 11 percent, respectively). Survival rates after complete resection of a second and third metastasis were not different from those after initial metastasectomy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The strongest predictors of prolonged survival were a disease-free interval from nephrectomy to detection of metastases of greater than one year (55 versus 9 percent five-year overall survival); a single site versus multiple sites of metastases (54 versus 29 percent five-year survival), especially if the site was the lung; an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1  (<a class="graphic graphic_table graphicRef72901" href="/d/graphic/72901.html" rel="external">table 2</a>); and the absence of prior cytotoxic chemotherapy or of significant recent weight loss.</p><p></p><p>A study published in the targeted therapy era also found that the number of metastatic sites (≥2 versus &lt;2) and sarcomatoid features was associated with recurrence after complete metastasectomy [<a href="#rid19">19</a>]. </p><p>For patients who undergo complete resection of metastatic disease, surveillance is recommended. Outside of a clinical trial, systemic therapy should be reserved for patients with measurable disease recurrence. Two small randomized studies with vascular endothelial growth factor (VEGF)-targeted agents, <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> [<a href="#rid20">20</a>] and <a class="drug drug_general" data-topicid="9524" href="/d/drug information/9524.html" rel="external">pazopanib</a> [<a href="#rid21">21</a>], showed no benefit after complete resection of metastatic disease (M1NED). (See  <a class="medical medical_review" href="/d/html/2969.html" rel="external">"Surveillance for metastatic disease after definitive treatment for renal cell carcinoma"</a> and  <a class="medical medical_review" href="/d/html/15719.html" rel="external">"Overview of the treatment of renal cell carcinoma"</a>.)</p><p class="headingAnchor" id="H1479880232"><span class="h3">Residual disease after systemic therapy</span><span class="headingEndMark"> — </span>Resection of metastatic disease appears to be effective following systemic therapy in carefully selected patients. The eligibility criteria, however, are not standardized and therefore require multidisciplinary consultation. </p><p>In the cytokine era, resection of residual disease after achieving a partial remission from systemic therapy with interleukin-2 (IL-2) frequently resulted in disease-free survival for significant periods [<a href="#rid22">22,23</a>]. This was illustrated in a series of 31 selected patients with RCC who had a partial or complete response to systemic IL-2 and then underwent resection of relapsing or residual disease; the two-year progression-free survival was 37 percent [<a href="#rid23">23</a>]. Subsequent evaluation has confirmed that most of these patients remain disease free, with follow-up beyond 10 years in some cases [<a href="#rid24">24</a>]. Pathology of the resected lesions frequently reveals an active lymphoid infiltrate surrounding the residual tumor or occasionally no evidence of residual tumor. (See  <a class="medical medical_review" href="/d/html/2984.html" rel="external">"Systemic therapy of advanced clear cell renal carcinoma"</a>.) </p><p>Data for patients treated initially with antiangiogenic therapy are more limited and of shorter duration, but they also support the role of metastasectomy in appropriately selected patients. In an observational multicenter series of 22 patients, 11 remained disease free at a median of 43 weeks after surgery [<a href="#rid25">25</a>]. At a median follow-up of over two years, 21 patients were alive.</p><p class="headingAnchor" id="H1462133"><span class="h2">Evidence for metastasectomy</span></p><p class="headingAnchor" id="H6"><span class="h3">Thoracic metastases</span><span class="headingEndMark"> — </span>Surgical resection of isolated lung metastases in carefully selected patients has been associated with a 20 to 50 percent five-year survival. Complete resection of lung-only metastases is associated with markedly improved survival as compared with incomplete resection (five-year cancer-specific survival 73.6 versus 19 percent, respectively) [<a href="#rid26">26</a>]. The general criteria, techniques, and results for surgical resection of pulmonary metastases from solid tumors are discussed separately. (See  <a class="medical medical_review" href="/d/html/2796.html" rel="external">"Surgical resection of pulmonary metastases: Outcomes by histology"</a> and  <a class="medical medical_review" href="/d/html/7815.html" rel="external">"Surgical resection of pulmonary metastases: Benefits, indications, preoperative evaluation, and techniques"</a>.)</p><p>Isolated thoracic lymph node metastases of RCC can be treated with systematic lymph node dissection. In a series of 15 patients, the median disease-free interval was 40 months (range 0 to 171 months) before isolated thoracic lymph node metastases were detected. After surgery, the survival rates at one, three, and five years were 93, 73, and 73 percent, respectively, and 65 percent of the patients were free of local recurrence at five years. Perioperative morbidity and mortality rates were low [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H7"><span class="h3">Isolated bone metastases</span><span class="headingEndMark"> — </span>Excision of bone metastases may be considered in carefully selected patients for both pain relief and tumor control [<a href="#rid24">24,28-30</a>]. In one series, 295 consecutive patients with metastatic RCC who had a solitary lesion, intractable pain, or impending fracture underwent resection [<a href="#rid29">29</a>]. Overall, the one- and five-year survival rates were 47 and 11 percent. The best results were seen in patients who had either a solitary bone lesion or multiple bone-only metastases. Stereotactic radiosurgery (SRS) is increasingly being used to treat oligometastatic bony disease and may extend targeted-therapy treatment [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/d/html/2805.html" rel="external">"Radiation therapy for the management of painful bone metastases"</a>.)</p><p class="headingAnchor" id="H8"><span class="h3">Brain metastases</span><span class="headingEndMark"> — </span>Brain lesions have been traditionally treated with surgical resection, whole-brain irradiation, or SRS. However, regardless of the treatment approach, the prognosis is poor, and median survival in patients with brain metastases is approximately nine months [<a href="#rid32">32</a>]. For these patients, poor prognostic factors for overall survival include [<a href="#rid33">33</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Performance status at the start of therapy &lt;80 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Diagnosis to treatment time &lt;12 months</p><p class="bulletIndent1"><span class="glyph">●</span>&gt;3 sites of brain metastases</p><p></p><p>SRS alone may be an attractive therapeutic option for patients with incidentally identified brain metastases from RCC [<a href="#rid34">34,35</a>]. In one report of 19 patients presenting with incidentally detected, asymptomatic brain metastases, local control was achieved in 95 percent with SRS [<a href="#rid34">34</a>]. At a mean of 450 days, approximately 20 percent remained free from progression in the central nervous system. (See  <a class="medical medical_review" href="/d/html/5212.html" rel="external">"Overview of the treatment of brain metastases", section on 'Single brain metastasis'</a>.)</p><p>A study of the Surveillance, Epidemiology, and End Results (SEER) database found that 12 percent of patients with metastatic RCC had synchronous brain metastasis, and 20 percent of patients with brain metastasis had brain-only metastasis. Compared with those with brain and other metastases, patients with brain-only metastasis were more likely to undergo cytoreductive nephrectomy (40.8 versus 20.4 percent) and had better prognosis after the surgery (median survival 33 versus 11 months) [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H2348386964"><span class="h3">Liver metastases</span><span class="headingEndMark"> — </span>Despite the negative impact of liver metastases on survival [<a href="#rid37">37</a>], resections of solitary metachronous liver metastases are possible, although the morbidity may be high [<a href="#rid38">38</a>]. Contemporary reports suggest that with careful patient selection, two-year survival is greater than 50 percent. Factors that may identify appropriate patients for hepatic metastasectomy include those in whom surgery is being performed with curative intent, an interval of more than 24 months from RCC diagnosis to development of liver metastases, tumor size less than 5 cm, and the feasibility of repeat hepatectomy if necessary [<a href="#rid39">39</a>].</p><p class="headingAnchor" id="H2348386971"><span class="h3">Thyroid metastases</span><span class="headingEndMark"> — </span>RCC commonly metastasizes to the thyroid gland [<a href="#rid40">40</a>]. Fine needle aspiration is essential to make this diagnosis. Limited data suggest that metastasectomy may confer a survival advantage. In one study of 97 patients with thyroid metastases (22 percent from a renal primary), median survival time was 30 and 12 months for those who underwent metastasectomy compared with those who did not [<a href="#rid40">40</a>]. Poor prognostic indicators were patient age &gt;70 years and prior nephrectomy for contralateral renal metastases.</p><p class="headingAnchor" id="H2348386978"><span class="h3">Pancreatic metastases</span><span class="headingEndMark"> — </span>Patients with pancreatic metastases seem to have a better prognosis, which may be a result of a more indolent biology [<a href="#rid41">41</a>]. In addition, patients who present with pancreatic metastases also respond better to targeted agents [<a href="#rid42">42</a>], although the reason for this is unknown. A systematic literature review of 384 patients with RCC metastases to the pancreas managed with (n = 321) or without (n = 73) metastasectomy revealed five-year overall survivals of 73 and 14 percent, respectively [<a href="#rid43">43</a>]. The postoperative in-hospital mortality associated with pancreatic resection was 2.8 percent. The presence of extrapancreatic RCC metastases was associated with worse disease-free survival, and symptomatic metastases were associated with worse overall survival. Surprisingly, the size of the largest tumor resected, number of pancreatic metastases, type of pancreatic resection, and interval from diagnosis of RCC to pancreatic metastasis were not predictive of survival. </p><p class="headingAnchor" id="H2348386900"><span class="h3">Local recurrence</span><span class="headingEndMark"> — </span>Although the majority of patients who develop a local soft tissue recurrence die of metastatic disease, the limited data suggest that resection of the recurrence may prolong survival in carefully selected patients [<a href="#rid44">44-46</a>]. As with metastatic disease, patients with a longer time to recurrence following nephrectomy and with small-volume recurrent disease tend to do better. </p><p class="headingAnchor" id="H10"><span class="h1">PALLIATIVE NEPHRECTOMY</span><span class="headingEndMark"> — </span>Nephrectomy has been used to control severe local symptoms from the primary tumor such as significant pain or bleeding needing blood transfusions [<a href="#rid47">47,48</a>]. In these cases, we recommend proceeding with palliative nephrectomy, although systemic therapy may also be justified.</p><p>Alternative approaches to symptom palliation are illustrated by the following examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Pain can be managed with analgesics or angioinfarction. (See  <a class="medical medical_review" href="/d/html/2814.html" rel="external">"Cancer pain management with opioids: Optimizing analgesia"</a> and  <a class="medical medical_review" href="/d/html/2815.html" rel="external">"Cancer pain management: Role of adjuvant analgesics (coanalgesics)"</a> and  <a class="medical medical_review" href="/d/html/2798.html" rel="external">"Cancer pain management: Use of acetaminophen and nonsteroidal anti-inflammatory drugs"</a> and  <a class="medical medical_review" href="/d/html/14248.html" rel="external">"Interventional therapies for chronic pain"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hematuria due to renal cell carcinoma (RCC) can be managed by renal angioinfarction, which entails femoral artery puncture and the subsegmental injection of polyvinyl alcohol particles into the renal vessels. However, it may be associated with a high complication rate, including the risk for the development of postembolization syndrome (PES), consisting of intractable pain and nausea, fever, and potentially a paralytic ileus. In one retrospective study that included over 100 patients (34 of whom underwent angioinfarction for palliation), 75 patients (66 percent) experienced a complication [<a href="#rid49">49</a>]. The most common complications were PES, leukocytosis, and fever, which were reported in 44, 28, and 13 percent, respectively; there were no reports of a paralytic ileus.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The consequences of colic due to obstruction with a clot can be minimized with ureteral stents and hydration. (See  <a class="medical medical_review" href="/d/html/15182.html" rel="external">"Placement and management of indwelling ureteral stents", section on 'Indications for stent placement'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypercalcemia, fatigue, fever, and other systemic symptoms are often controlled with nonsteroidal anti-inflammatory drugs, bisphosphonates, hydration, and/or appetite stimulants in addition to effective systemic therapy for the disease. (See  <a class="medical medical_review" href="/d/html/850.html" rel="external">"Treatment of hypercalcemia"</a>.)</p><p></p><p class="headingAnchor" id="H4193321583"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/119821.html" rel="external">"Society guideline links: Cancer of the kidney and ureters"</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">SUMMARY AND RECOMMENDATIONS</span><span class="headingEndMark"> — </span>Patients who present with metastatic renal cell carcinoma (RCC) or who develop metastases or recurrent disease following prior treatment are generally managed with systemic therapy. (See  <a class="medical medical_review" href="/d/html/2984.html" rel="external">"Systemic therapy of advanced clear cell renal carcinoma"</a> and  <a class="medical medical_review" href="/d/html/2962.html" rel="external">"Antiangiogenic and molecularly targeted therapy for advanced or metastatic clear cell renal carcinoma"</a>.)</p><p>Surgery retains an important role in the management of carefully selected patients:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients who have favorable (no risk factor) or low-intermediate risk (one risk factor) metastatic RCC at presentation, a good performance status, and a resectable primary tumor with low tumor burden outside the kidney, we suggest upfront debulking (cytoreductive) nephrectomy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). In such patients, cytoreductive nephrectomy should be performed before systemic therapy (either antiangiogenic therapy or immune checkpoint inhibitor therapy). (See <a class="local">'Cytoreductive nephrectomy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with one to three readily resectable metastases at presentation or who relapse following initial surgical treatment (nephrectomy) but have a disease-free interval &gt;1 year, we suggest metastasectomy rather than immediate initiation of systemic therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). This approach has been associated with prolonged disease-free survival in selected patients. (See <a class="local">'Metastasectomy'</a> above.)</p><p></p><p class="bulletIndent1">Patients who undergo complete resection of metastatic disease should undergo surveillance. Outside of a clinical trial, systemic therapy should be reserved for patients with measurable disease. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although palliative nephrectomy has been used to control severe local symptoms from the primary tumor (eg, pain, bleeding), systemic therapy and interventional angioinfarction techniques are also reasonable options. (See <a class="local">'Palliative nephrectomy'</a> above.) </p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Rini BI, Dorff TB, Elson P, et al. A prospective observational study of metastatic renal cell carcinoma (mRCC) prior to initiation of systemic therapy. J Clin Oncol 2014; 32:5s (suppl; abstr 4520). Available at: https://meetinglibrary.asco.org/record/92277/abstract (Accessed on May 06, 2022).</li><li><a class="nounderline abstract_t">Vasselli JR, Yang JC, Linehan WM, et al. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. J Urol 2001; 166:68.</a></li><li><a class="nounderline abstract_t">Pantuck AJ, Zisman A, Dorey F, et al. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer 2003; 97:2995.</a></li><li><a class="nounderline abstract_t">Pantuck AJ, Zisman A, Dorey F, et al. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol 2003; 169:2076.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20:289.</a></li><li><a class="nounderline abstract_t">Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27:5794.</a></li><li><a class="nounderline abstract_t">Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345:1655.</a></li><li><a class="nounderline abstract_t">Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001; 358:966.</a></li><li><a class="nounderline abstract_t">Méjean A, Ravaud A, Thezenas S, et al. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. N Engl J Med 2018; 379:417.</a></li><li><a class="nounderline abstract_t">Bex A, Mulders P, Jewett M, et al. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial. JAMA Oncol 2019; 5:164.</a></li><li><a class="nounderline abstract_t">Bex A, Albiges L, Ljungberg B, et al. Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma. Eur Urol 2018; 74:805.</a></li><li><a class="nounderline abstract_t">Méjean A, Ravaud A, Thezenas S, et al. Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy? Eur Urol 2021; 80:417.</a></li><li><a class="nounderline abstract_t">Heng DY, Wells JC, Rini BI, et al. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol 2014; 66:704.</a></li><li><a class="nounderline abstract_t">Hanna N, Sun M, Meyer CP, et al. Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study. J Clin Oncol 2016; 34:3267.</a></li><li class="breakAll">ASCO GU 2020: Cytoreductive nephrectomy for metastatic renal cell carcinoma treated with immune checkpoint inhibitors or targeted therapy. Available at: https://www.urotoday.com/conference-highlights/asco-gu-2020/asco-gu-2020-kidney-cancer/119346-asco-gu-2020-cytoreductive-nephrectomy-for-metastatic-renal-cell-carcinoma-treated-with-immune-checkpoint-inhibitors-or-targeted-therapy.html (Accessed on April 28, 2020).</li><li><a class="nounderline abstract_t">Silagy AW, Kotecha RR, Weng S, et al. Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma. Cancer 2021; 127:3946.</a></li><li><a class="nounderline abstract_t">Roussel E, Beuselinck B, Albersen M. Three Years After CARMENA: What Have We Learned? Eur Urol 2021; 80:425.</a></li><li><a class="nounderline abstract_t">Kavolius JP, Mastorakos DP, Pavlovich C, et al. Resection of metastatic renal cell carcinoma. J Clin Oncol 1998; 16:2261.</a></li><li><a class="nounderline abstract_t">Takagi T, Fukuda H, Ishihara H, et al. Predictive factors for recurrence after complete metastasectomy in patients with metastatic renal cell carcinoma in the targeted therapy era. Urol Oncol 2020; 38:515.</a></li><li><a class="nounderline abstract_t">Procopio G, Apollonio G, Cognetti F, et al. Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study. Eur Urol Oncol 2019; 2:699.</a></li><li class="breakAll">Appleman JP, Puligandla M, Pal SK, et al. Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810). J Clin Oncol 2019: 37 (suppl; abstr 4502). Available at: https://meetinglibrary.asco.org/record/171840/abstract (Accessed on May 27, 2020).</li><li><a class="nounderline abstract_t">Fleischmann JD, Kim B. Interleukin-2 immunotherapy followed by resection of residual renal cell carcinoma. J Urol 1991; 145:938.</a></li><li><a class="nounderline abstract_t">Lee DS, White DE, Hurst R, et al. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy. Cancer J Sci Am 1998; 4:86.</a></li><li><a class="nounderline abstract_t">Yang JC, Abad J, Sherry R. Treatment of oligometastases after successful immunotherapy. Semin Radiat Oncol 2006; 16:131.</a></li><li><a class="nounderline abstract_t">Karam JA, Rini BI, Varella L, et al. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol 2011; 185:439.</a></li><li><a class="nounderline abstract_t">Alt AL, Boorjian SA, Lohse CM, et al. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer 2011; 117:2873.</a></li><li><a class="nounderline abstract_t">Sponholz S, Schirren M, Oguzhan S, et al. Long-term Outcome After Resection of Isolated Thoracic Lymph Node Metastases of Renal Cell Cancer. Ann Thorac Surg 2020; 109:262.</a></li><li><a class="nounderline abstract_t">Kollender Y, Bickels J, Price WM, et al. Metastatic renal cell carcinoma of bone: indications and technique of surgical intervention. J Urol 2000; 164:1505.</a></li><li><a class="nounderline abstract_t">Lin PP, Mirza AN, Lewis VO, et al. Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am 2007; 89:1794.</a></li><li><a class="nounderline abstract_t">Higuchi T, Yamamoto N, Hayashi K, et al. Long-term patient survival after the surgical treatment of bone and soft-tissue metastases from renal cell carcinoma. Bone Joint J 2018; 100-B:1241.</a></li><li><a class="nounderline abstract_t">Straka C, Kim DW, Timmerman RD, et al. Ablation of a site of progression with stereotactic body radiation therapy extends sunitinib treatment from 14 to 22 months. J Clin Oncol 2013; 31:e401.</a></li><li><a class="nounderline abstract_t">Gore ME, Hariharan S, Porta C, et al. Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer 2011; 117:501.</a></li><li><a class="nounderline abstract_t">Vickers MM, Al-Harbi H, Choueiri TK, et al. Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium. Clin Genitourin Cancer 2013; 11:311.</a></li><li><a class="nounderline abstract_t">Marko NF, Angelov L, Toms SA, et al. Stereotactic radiosurgery as single-modality treatment of incidentally identified renal cell carcinoma brain metastases. World Neurosurg 2010; 73:186.</a></li><li><a class="nounderline abstract_t">Shuch B, La Rochelle JC, Klatte T, et al. Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival. Cancer 2008; 113:1641.</a></li><li><a class="nounderline abstract_t">Daugherty M, Daugherty E, Jacob J, et al. Renal cell carcinoma and brain metastasis: Questioning the dogma of role for cytoreductive nephrectomy. Urol Oncol 2019; 37:182.e9.</a></li><li><a class="nounderline abstract_t">McKay RR, Kroeger N, Xie W, et al. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol 2014; 65:577.</a></li><li><a class="nounderline abstract_t">Stief CG, Jáhne J, Hagemann JH, et al. Surgery for metachronous solitary liver metastases of renal cell carcinoma. J Urol 1997; 158:375.</a></li><li><a class="nounderline abstract_t">Alves A, Adam R, Majno P, et al. Hepatic resection for metastatic renal tumors: is it worthwhile? Ann Surg Oncol 2003; 10:705.</a></li><li><a class="nounderline abstract_t">Hegerova L, Griebeler ML, Reynolds JP, et al. Metastasis to the thyroid gland: report of a large series from the Mayo Clinic. Am J Clin Oncol 2015; 38:338.</a></li><li class="breakAll">Kalra S, Atkinson BJ, Matrana MR, et al. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. J Clin Oncol 2014; 32 (suppl 4; abstr 527). Available at: https://meetinglibrary.asco.org/record/90696/abstract (Accessed on May 06, 2022).</li><li><a class="nounderline abstract_t">Medioni J, Choueiri TK, Zinzindohoué F, et al. Response of renal cell carcinoma pancreatic metastasis to sunitinib treatment: a retrospective analysis. J Urol 2009; 181:2470.</a></li><li><a class="nounderline abstract_t">Tanis PJ, van der Gaag NA, Busch OR, et al. Systematic review of pancreatic surgery for metastatic renal cell carcinoma. Br J Surg 2009; 96:579.</a></li><li><a class="nounderline abstract_t">Schrodter S, Hakenberg OW, Manseck A, et al. Outcome of surgical treatment of isolated local recurrence after radical nephrectomy for renal cell carcinoma. J Urol 2002; 167:1630.</a></li><li><a class="nounderline abstract_t">Itano NB, Blute ML, Spotts B, Zincke H. Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy. J Urol 2000; 164:322.</a></li><li><a class="nounderline abstract_t">Margulis V, McDonald M, Tamboli P, et al. Predictors of oncological outcome after resection of locally recurrent renal cell carcinoma. J Urol 2009; 181:2044.</a></li><li><a class="nounderline abstract_t">Flanigan RC. Role of surgery in metastatic renal cell carcinoma. Semin Urol 1989; 7:191.</a></li><li><a class="nounderline abstract_t">Middleton AW Jr. Indications for and results of nephrectomy for metastatic renal cell carcinoma. Urol Clin North Am 1980; 7:711.</a></li><li><a class="nounderline abstract_t">Vora A, Brodsky R, Nolan J, et al. Incidence of postembolization syndrome after complete renal angioinfarction: a single-institution experience over four years. Scand J Urol 2014; 48:245.</a></li></ol></div><div id="topicVersionRevision">Topic 2963 Version 45.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://meetinglibrary.asco.org/record/92277/abstract" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Rini BI, Dorff TB, Elson P, et al. A prospective observational study of metastatic renal cell carcinoma (mRCC) prior to initiation of systemic therapy. J Clin Oncol 2014; 32:5s (suppl; abstr 4520). Available at: https://meetinglibrary.asco.org/record/92277/abstract (Accessed on May 06, 2022).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11435825" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12784334" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12771723" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11773181" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19826129" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11759643" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11583750" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29860937" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30543350" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30177291" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34187771" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24931622" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27325852" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27325852" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34286865" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34325948" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Three Years After CARMENA: What Have We Learned?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9626229" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Resection of metastatic renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32146128" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Predictive factors for recurrence after complete metastasectomy in patients with metastatic renal cell carcinoma in the targeted therapy era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31542243" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31542243" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2016805" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Interleukin-2 immunotherapy followed by resection of residual renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9532410" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16564448" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Treatment of oligometastases after successful immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21167518" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21692048" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Survival after complete surgical resection of multiple metastases from renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31499030" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Long-term Outcome After Resection of Isolated Thoracic Lymph Node Metastases of Renal Cell Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11025692" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Metastatic renal cell carcinoma of bone: indications and technique of surgical intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17671020" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Patient survival after surgery for osseous metastases from renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30168767" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Long-term patient survival after the surgical treatment of bone and soft-tissue metastases from renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23796996" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Ablation of a site of progression with stereotactic body radiation therapy extends sunitinib treatment from 14 to 22 months.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20862748" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Sunitinib in metastatic renal cell carcinoma patients with brain metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23684422" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20860956" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Stereotactic radiosurgery as single-modality treatment of incidentally identified renal cell carcinoma brain metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18671240" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30528396" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Renal cell carcinoma and brain metastasis: Questioning the dogma of role for cytoreductive nephrectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23962746" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9224306" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Surgery for metachronous solitary liver metastases of renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12839857" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Hepatic resection for metastatic renal tumors: is it worthwhile?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23799287" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Metastasis to the thyroid gland: report of a large series from the Mayo Clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23799287" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Metastasis to the thyroid gland: report of a large series from the Mayo Clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19371877" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Response of renal cell carcinoma pancreatic metastasis to sunitinib treatment: a retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19434703" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Systematic review of pancreatic surgery for metastatic renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11912377" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Outcome of surgical treatment of isolated local recurrence after radical nephrectomy for renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10893575" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19286220" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Predictors of oncological outcome after resection of locally recurrent renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2481332" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Role of surgery in metastatic renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6161461" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Indications for and results of nephrectomy for metastatic renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24215333" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Incidence of postembolization syndrome after complete renal angioinfarction: a single-institution experience over four years.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
